Advertisement

Reducing costs and improving compliance

  • William W. Neal
    Correspondence
    Address for reprints: William W. Neal, MD, Veterans Administration Medical Center, 4500 South Lancaster Road, Dallas, Texas 75216.
    Affiliations
    From the Participating Investigator, Cooperative Studies Program on Antihypertensive Agents, Veterans Administration Medical Center, Dallas, Texas U.S.A.
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      The cost-effectiveness of antihypertensive therapy is defined as the costs of treatment less the savings from the prevention of stroke and myocardial infarction, relative to the therapeutic effectiveness of treatment. Since antihypertensive therapy actually increases the dollar cost of medical care, the use of more expensive agents needs to be justified in terms of better blood pressure control, improved quality of life, and reduced cardiovascular morbidity and mortality. Data from the clinical trials have not shown the more expensive agents such as angiotensin-converting enzyme inhibitors and calcium channel blockers to be superior to the less expensive agents such as diuretic drugs in reducing blood pressure or cardiovascular morbidity and mortality.
      Poor compliance may reduce both the effectiveness and cost-effectiveness of treatment. Physicians must play an active role in promoting compliance by assuring the patient's ability to incorporate the prescribed dosage regimen into daily routine, by actively monitoring compliance, by modifying the regimen appropriately to remove the cause of noncompliance, and by switching medication if it is ineffective or if adverse effects occur.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Weinstein MC
        • Stason WB
        Cost-effectiveness of interventions to prevent or treat coronary heart disease.
        Annu Rev Public Health. 1985; 6: 41-63
        • Helgeland A
        • Hagelund CH
        • Strommen R
        • Tretli S
        Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension.
        Lancet. 1986; 1: 872-875
        • Croog SH
        • Levine S
        • Testa MA
        • Brown B
        • Bulpitt C
        • Jenkins CD
        • Klerman G
        • Williams G
        The effects of antihypertensive therapy on the quality of life.
        N Engl J Med. 1986; 314: 1657-1664
        • Jenkins AC
        • Knill JR
        • Dreslinski GR
        Captopril in the treatment of the elderly hypertensive patient.
        Arch Intern Med. 1985; 145: 2029-2031
        • Moser M
        • Lunn J
        Responses to captopril and hydrochlorothiazide in black patients with hypertension.
        Clin Pharmacol Ther. 1982; 32: 307-312
      1. Arch Intern Med. 1988; 148: 1023-1038
        • Ayd Jr, FJ
        Single daily dose of antidepressants.
        JAMA. 1974; 230: 263-264
        • Nelson EC
        • Stason WB
        • Neutra RR
        • Solomon HS
        Identification of the noncompliant hypertensive patient.
        Prev Med. 1980; 9: 504-517
        • Inui TS
        • Yourtee EL
        • Williamson JW
        Improved outcomes in hypertension after physician tutorials.
        Ann Intern Med. 1976; 84: 646-651